Nykredit A S Makes New Investment in Edwards Lifesciences Corporation $EW

Key Points

• Nykredit A/S purchased 212,551 shares of Edwards Lifesciences in the second quarter, valued at approximately $19.2 million. Institutional investors collectively own 79.46% of the company.
• Analysts remain broadly optimistic, with 17 Buy ratings and six Holds producing a consensus “Moderate Buy” rating and an average price target of $100.27; targets range as high as $110.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus a $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year. Shares recently opened at $88.22.

Nykredit A S purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 212,551 shares of the medical research company's stock, valued at approximately $19,227,000.

Other institutional investors have also made changes to their positions in the company. Parkside Financial Bank & Trust lifted its holdings in shares of Edwards Lifesciences by 37.3% during the second quarter. Parkside Financial Bank & Trust now owns 1,953 shares of the medical research company's stock worth $177,000 after buying an additional 531 shares during the last quarter. Corient Private Wealth LP grew its stake in shares of Edwards Lifesciences by 1,028.9% in the second quarter. Corient Private Wealth LP now owns 250,101 shares of the medical research company's stock worth $22,624,000 after acquiring an additional 227,947 shares during the last quarter. HighTower Advisors LLC increased its position in Edwards Lifesciences by 1.4% during the second quarter. HighTower Advisors LLC now owns 149,485 shares of the medical research company's stock worth $13,522,000 after acquiring an additional 2,101 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Edwards Lifesciences during the second quarter worth $61,441,000. Finally, Vancity Investment Management Ltd raised its stake in Edwards Lifesciences by 15.8% during the 2nd quarter. Vancity Investment Management Ltd now owns 167,876 shares of the medical research company's stock valued at $15,186,000 after purchasing an additional 22,881 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on EW. Evercore restated an "outperform" rating and issued a $100.00 price target on shares of Edwards Lifesciences in a research report on Monday, July 6th. Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their price objective for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Weiss Ratings restated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Truist Financial upped their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a research note on Thursday, July 16th. Finally, Citigroup raised their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $88.22 on Friday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The stock has a market capitalization of $50.80 billion, a PE ratio of 50.70, a PEG ratio of 2.31 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock's fifty day moving average is $88.56 and its 200-day moving average is $85.91.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences's quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity

In other news, VP Daniel Lippis sold 619 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president directly owned 17,984 shares of the company's stock, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 5,664 shares of company stock valued at $511,918. 0.31% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.